Try GOLD - Free
Bioethics vis-a-vis Biosimilars
IP ERA
|November - December 2016
With India moving from strength to strength in establishment of biosimilars as the current and next step of affordable healthcare, the need of the hour is to understand the regulatory guidelines and their implementation as per current requirements.
-
The term “bioethics” was first coined in 1971 to signify the combination of biological sciences with humanistic knowledge. However, now it can be annotated as the application of ethics to the field of medicine and healthcare. The area of bioethics entails a vast span of concerns ranging from difficult private decisions in respect to clinical settings to the much talked about controversies surrounding stem cell research to implications of reproductive technologies and further broader concerns which include international human subject research, public policy in healthcare and allocation of scarce resources. Bioethics is thus the resultant controversy that results from the advancement of medicine or technology thus rendering the term to hold a fluid connotation. Bioethics brings to the fore fundamental issues and values arising from basic human rights such as the right to life and health, bodily integrity etc.
Usually bioethics as a notion entails discussion amongst experts from a wide range of disciplines – legal, philosophical, theological, nursing, medicine etc. However, the whole world woke up to discussions on bioethics in medicine in 1997 as the sheep Dolly took her first breath. The ethical issues with reproductive cloning included genetic modification and damage, health risks to the mother and the foetus, putting at risk the life contained within the embryo and the commodification of human life countered with the benefits and advancement of medical technology resulting from ‘Somatic Cell Nuclear Transfer’ thus resulting in a veritable plethora of debates.
This story is from the November - December 2016 edition of IP ERA.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM IP ERA
IP ERA
Bioethics vis-a-vis Biosimilars
With India moving from strength to strength in establishment of biosimilars as the current and next step of affordable healthcare, the need of the hour is to understand the regulatory guidelines and their implementation as per current requirements.
4 mins
November - December 2016
IP ERA
Tackling Online Employment Frauds
Efforts need to be taken at all levels – enforcement agencies, government institutions, corporations and the Internet users themselves – to curb this rising menace.
6 mins
November - December 2016
IP ERA
Google V. Equustek Solutions: The Cost of Doing Business?
Whether this is a simple case of the cost of doing business or just another case of insisting that Internet service providers and search engines become Internet police, there should be better parameters in place to protect the freedom of speech and prevent the abuse of the system.
8 mins
January - February 2017 Issue
IP ERA
Germany Hailed as an Arena for Solving International Patent Disputes
Indian companies can enforce patents in Germany not only in cases where the opponent operates in Germany but also in cases where activities of the opponent have bearing on Germany. Even in a litigation where Germany is only marginally affected, Indian patentees may have a standing in Germany and be able to sue opponents from foreign countries such as USA, Japan, China and even India.
6 mins
November - December 2016
IP ERA
Playing the Balancing Game
In order to attract foreign investment and encourage technology transfer, the government needs to take both consumers’ and private sector’s interests into account. There is no doubt that a balance is needed such that exclusive rights are protected but at the same time, this ‘should not’ lead to abuse of dominant position by the rights’ holder.
6 mins
November - December 2016
IP ERA
Biological Diversity Act, 2002: An Overview
A look at the provisions and regulations issued under this Act that came into force entirely in 2004 mainly to give effect to the UN Convention on Biological Diversity held at Rio De Janeiro in 1992.
7 mins
January - February 2017 Issue
IP ERA
Flying high: PTAB's Pilot Program For One-Judge Reviews
The pilot program proposed by the Patent Trial and Appeal Board (PTAB) is a winwin for both patent owners and the PTAB as it offers the former a chance to try one’s case before an objective trial-phase panel, while the latter stands to benefit too as two of three judges who would have been involved in the institution phase of an IPR are now free to look into other matters…
5 mins
January - February 2017 Issue
IP ERA
IP-led Innovation As Driver Of Indian Economy: The Role Of Businesses
Given the new policy initiatives by the Government of India that provide significant opportunity, Indian companies must develop IP-based innovative products and solutions that lead to business and economic growth.
8 mins
January - February 2017 Issue
Translate
Change font size